Company intelligence / Profile preview

ImageneBio

San Diego, California, United Stateslinkedin.com ↗

Ownership: Public · IMA
Development stage: Other

Overview

IMG‑007, the lead program—a non-depleting anti-OX40 monoclonal antibody—has completed a Phase 2a trial in moderate-to-severe atopic dermatitis. The trial demonstrated marked and durable clinical activity with a well-tolerated safety profile. The company is now positioned to advance into later-stage development and potentially expand into other immunological indications.

Therapeutic areas: Dermatology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

14 assets

IMG-007

13 more assets in the full pipeline.

Request access →

Partnerships

Deep Track CapitalForesite CapitalRTW InvestmentsBVF Partners L.P.Blue Owl Healthcare OpportunitiesOmega FundsOrbiMed

Financials

Market cap: $57M
Total revenue: $0
Enterprise value: $-77.3M

Beyond the preview

Go deeper on ImageneBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImageneBio.

Explore the full profile